Healthy Subjects (HS)
Conditions
Keywords
Dose escaltion
Brief summary
This is a phase I clinical trial with a single dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects
Detailed description
Four dose groups were set up, 75 mg, 150 mg, 300 mg, and 500 mg, respectively. Eight subjects (6 subjects received JH013 injection, 2 subjects received placebo) were planned to be included in each dose group for subcutaneous administration.The safety and tolerability within 48 hours after administration were first observed in each dose group with 2 subjects (1 subject receiving JH013 injection and 1 subject receiving placebo),after that, the remaining 6 subjects (5 receiving JH013 injection and 1 receiving placebo) were enrolled. Each subject may only participate in this trial in one dose group, and the next higher dose trial will only be allowed after it has been determined that the previous dose has been well safe and tolerated within 28 days of dosing (as determined by an independent, unblinded third-party physician in conjunction with the investigator and sponsor). When the safety evaluation meets the termination criteria during the dose escalation process, the dose between the dose group and the previous dose group can be returned if necessary after discussion by the investigator and the sponsor, and the maximum safe tolerated dose can be explored again. When the dose is escalated to the highest dose set by the protocol and the dose termination criteria are not met, it is up to the investigator and the sponsor to discuss whether to expand to a higher dose.
Interventions
DRUGJH013 injection
JH013 injection is a BAFF-R inhibitor monoclonal antibody
DRUGPlacebo
JH013 injections placebo
Sponsors
Biotech Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult male or female aged 18-55 years (age including cut-off values); * There were no abnormalities in clinically significant vital signs, physical examination, laboratory tests, and 12-lead ECG; * Weight ≥ 50 kg for males and ≥45 kg for females; Body mass index (BMI) between 18.0 and 26 kg/m2 (including cut-off values, body mass index = weight/height2); * Females of potential childbearing potential with a negative blood β-HCG test within 72 hours prior to dosing (postmenopausal women who have amenorrhea for at least 12 months are considered non-childbearing and women who are known to have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or ligation, and a pregnancy test is not required); * Subjects understand and comply with the study process, participate voluntarily, and sign the informed consent form
Exclusion criteria
* Subject has a history of malignancy prior to screening, or has been screened for malignancy, and the possibility of malignancy cannot be reasonably ruled out * Subject has a history of autoimmune disease prior to screening * γ interferon release assay results ≥ 2 times the upper limit of normal * Any history of infection requiring hospitalization or receiving antivirals, antibiotics, antifungals, antiparasitic drugs, or vaccinations within 4 weeks prior to the application of the study drug * Those who have positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody or syphilis antibody * Patients with a history of previous and/or current heart disease (including New York Heart Association Class III/IV heart failure), gastrointestinal, renal, endocrine, neurological, autoimmune, hematologic (including pancytopenia, aplastic anemia or anaemia, etc.), metabolic (including diabetes), severe lung disease and psychiatric illness * History of organ transplantation: such as heart, lung, kidney, liver, or hematopoietic stem cell transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety metrics | from Administration to Day57. | Including Adverse events defined by CTCAE 5.0（Common Terminology Criteria for Adverse Events Version 5.0) Version 5.0） |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CD45+CD3+T cell | from Administration to Day57. | Detection of CD45+CD3+T cell count and ratio blood |
| Drug immunogenicity | from Administration to Day57. | Detection of anti-drug antibodies in serum |
| t1/2 | from Administration to Day57. | Half-life |
| JH013 antibody | from Administration to Day57. | Detection of JH013 antibody occupancy in serum |
| CD45+CD19+ B cell | from Administration to Day57. | Detection CD45+CD19+ B cell count and ratio in blood |
| B cell activation factor (BAFF) | from Administration to Day57. | Detection B cell activation factor (BAFF) in serum |
| Cmax | from Administration to Day57. | maximum plasma concentration |
Contacts
Primary ContactWang Yucheng, Master
Outcome results
None listed